Groundwork underway for Athenex $200M manufacturing plant in upstate New York

Athenex plant rendering
Land clearing at the new site has begun, says Athenex, with construction slated to begin this summer. (Athenex)

Athenex, a Buffalo-based biotech, has begun site preparation for its $200 million manufacturing facility in Dunkirk, New York.

Land clearing at the site began recently, and construction is expected to begin later this summer with roof, exterior and glass likely to be up by the fourth quarter this year, Teresa Bair, an Athenex vice president, told the Observer.

The plant is scheduled to be fully operational by the first half of 2020 and will employee about 900 people, she said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Athenex announced plans for the facility nearly two years ago when it signed an agreement with the U.S. unit of German construction company M+W. When completed, the plant will be about 320,000 square feet.

The company, which was founded in 2002 as Kinex, focuses on oncology drugs of which it has said it has about six major clinical-stage candidate compounds. Athenex is also working with the municipal government of Chongqing in China for the construction of a pair of drug manufacturing plants at Banan where it can produce high-potency oncology active pharmaceutical ingredients.

Suggested Articles

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Sun Pharmaceutical has struggled to meet FDA expectations for the manufacturing lines at its key launch plant in Halol, India. The struggles continue.  …

Online pharmacy Valisure has criticized the FDA for what it deems as irrational standards in the levels of suspected carcinogens in the drug supply.